EMA’s Revised Guide On Additional Risk Minimization ‘Overly Detailed’
EU Pharma Association Pushes For Greater Use Of Digital Formats
Executive Summary: The European pharma industry federation believes the advice provided in the updated draft EU guideline on additional risk minimization measures is far too detailed, resulting in a lack of focus, information overlap and confusion.
You may also be interested in...
Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.
The UK government has revealed a number of changes it is making to the health care system in response to a report that found serious lapses regarding the safety of patients who were using certain treatments.
New EU guidance discusses the quality documentation needed for medicines that contain a device component for their delivery or use.